Source-grounded facts extracted from FATE THERAPEUTICS INC's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
FATE THERAPEUTICS INC shareholders approved Approval of an amendment to the Amended and Restated 2022 Stock Option and Incentive Plan to increase the number of shares of Common Stock reserved for issuance by 7,000,000 shares at the 2026-06-12 meeting.
“(iv) Approval of an amendment and restatement of the 2022 A&R Plan to increase the number of shares of Common Stock reserved for issuance thereunder. For Against Abstain Broker Non-Votes 46,645,607 14,304,810 100,245 26,083,760”
FATE THERAPEUTICS INC shareholders approved Non-binding advisory vote on the compensation of the Company’s named executive officers at the 2026-06-12 meeting.
“(iii) Non-binding advisory vote on the compensation of the Company’s named executive officers. For Against Abstain Broker Non-Votes 59,168,689 1,808,669 73,304 26,083,760”
FATE THERAPEUTICS INC shareholders approved Ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-12 meeting.
“(ii) Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. For Against Abstain Broker Non-Votes 86,552,927 308,582 272,913 0”
FATE THERAPEUTICS INC shareholders approved Election of Class I Directors at the 2026-06-12 meeting.
“(i) Election of Class I Directors. Director Nominee For Withheld Broker Non-Votes Robert S. Epstein, M.D., M.S. 59,332,820 1,717,842 26,083,760 Karin Jooss, Ph.D. 59,655,584 1,395,078 26,083,760 Laura J. Hamill 60,850,004 200,658 26,083,760”
FATE THERAPEUTICS INC reported financial results for the first quarter ended March 31, 2026.
“On May 13, 2026, Fate Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended March 31, 2026.”
FATE THERAPEUTICS INC announced a restructuring with charges of approximately $0.9 million to $1.2 million (approximately 12%).
“On August 7, 2025, the Company’s Board of Directors approved a corporate restructuring to streamline operations, reduce operating expenses, and extend cash runway (the “Restructuring”). In connection with the Restructuring, the Company committed to a reduction in total workforce by approximately 12% (the “RIF”). Affected employees were informed on August 12, 2025. The Company expects the RIF to be completed during the third quarter of 2025, and estimates that it will incur charges of approximately $0.9 million to $1.2 million for severance and other employee termination-related costs during the third quarter of 2025.”
FATE THERAPEUTICS INC: Increased authorized shares of Common Stock from 250,000,000 to 350,000,000 (effective 2025-05-29).
“to increase the number of authorized shares of Common Stock from 250,000,000 shares to 350,000,000 shares”
Timothy P. Coughlin departed as Director at FATE THERAPEUTICS INC.
“Concurrently with Mr. Abernethy’s election at the Annual Meeting, Timothy P. Coughlin’s term as a member of the Board and the Audit Committee thereof ended.”
Matthew Abernethy was appointed as Class III Director at FATE THERAPEUTICS INC.
“appointed Matthew Abernethy to the Board to serve as a Class III director”
Bahram Valamehr was appointed as President and Chief Executive Officer at FATE THERAPEUTICS INC.
“Bahram Valamehr, Ph.D., MBA has succeeded Mr. Wolchko in each of the Subsidiary Roles, effective as of January 1, 2025.”
J. Scott Wolchko retired as President, Chief Executive Officer, Chief Financial Officer at FATE THERAPEUTICS INC.
“J. Scott Wolchko retired from his positions as President, Chief Executive Officer (“CEO”), Chief Financial Officer, Treasurer, principal executive officer, principal financial officer and principal accounting officer of the Company, effective as of December 31, 2024”
Neelufar Mozaffarian was appointed as Class II director at FATE THERAPEUTICS INC.
“On July 29, 2024, the Board, following a recommendation from the Nominating and Corporate Governance Committee of the Board (the “NCG Committee”), appointed Neelufar Mozaffarian, M.D., Ph.D., FACR, to the Board, to serve as a Class II director and member of the NCG Committee and the Science and Technology Committee of the Board.”
J. Scott Wolchko was appointed as Chief Financial Officer at FATE THERAPEUTICS INC.
“On June 3, 2024, the board of directors (the “Board”) of Fate Therapeutics, Inc. (the “Company”) appointed J. Scott Wolchko, the Company’s President and Chief Executive Officer, to succeed Edward J. Dulac III as the Company’s Chief Financial Officer and also serve as the Company’s principal financial and accounting officer, effective immediately after Mr. Dulac’s resignation.”
Edward J. Dulac III resigned as Chief Financial Officer at FATE THERAPEUTICS INC.
“Mr. Dulac provided notice of his resignation from his position as the Company’s Chief Financial Officer on May 30, 2024, which resignation shall be effective as of June 14, 2024.”
J. Scott Wolchko was appointed as Chief Financial Officer at FATE THERAPEUTICS INC.
“The Company’s board of directors intends to appoint J. Scott Wolchko, the Company’s President and Chief Executive Officer, to succeed Mr. Dulac as the Company’s Chief Financial Officer and also serve as the Company’s principal financial and accounting officer, effective immediately after Mr. Dulac’s resignation.”
Edward J. Dulac III resigned as Chief Financial Officer at FATE THERAPEUTICS INC.
“On May 30, 2024, Edward J. Dulac III provided notice of his resignation from his position as Chief Financial Officer of Fate Therapeutics, Inc. (the “Company”), which will be effective June 14, 2024.”
FATE THERAPEUTICS INC reported financial results for the first quarter ended March 31, 2024.
“Fate Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024.”
FATE THERAPEUTICS INC entered into Securities Purchase Agreement with a fund affiliated with Redmile Group, LLC valued at approximately $20.0 million (effective 2024-03-19).
“On March 19, 2024, the Company entered into a securities purchase agreement (the “Purchase Agreement”) with a fund affiliated with Redmile Group, LLC (collectively, “Redmile”).”
FATE THERAPEUTICS INC entered into Underwriting Agreement with BofA Securities, Inc., Jefferies LLC and Leerink Partners LLC valued at $74.7 million (effective 2024-03-19).
“On March 19, 2024, Fate Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with BofA Securities, Inc., Jefferies LLC and Leerink Partners LLC, as representatives of the several underwriters (the “Underwriters”), pursuant to which the Company agreed to issue and sell 14,545,454 shares of the Company’s common stock, par value $0.001 per share (the “Shares”), at an offering price of $5.50 per Share (the “Offering”).”
FATE THERAPEUTICS INC reported financial results for fourth quarter and full year ended December 31, 2023.
“On February 26, 2024, Fate Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2023.”
FATE THERAPEUTICS INC terminated Open Market Sale Agreement with Jefferies LLC (effective 2023-11-08).
“Effective upon the execution of the Agreement, the Open Market Sale Agreement SM , dated November 4, 2021, by and between the Company and Jefferies (the “Prior Agreement”), was terminated and superseded by the Agreement.”
FATE THERAPEUTICS INC entered into Open Market Sale Agreement with Jefferies LLC valued at up to $100,000,000 (effective 2023-11-08).
“on November 8, 2023, the Company entered into an Open Market Sale Agreement SM (the “Agreement”) with Jefferies LLC (“Jefferies”) with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its Common Stock having an aggregate offering price of up to $100,000,000 (the “Placement Shares”), through Jefferies as its sales agent.”
FATE THERAPEUTICS INC reported financial results for the third quarter ended September 30, 2023.
“On November 8, 2023, Fate Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2023.”
FATE THERAPEUTICS INC reported second quarter ended June 30, 2023 results: revenue $0.9 million.
“June 30, 2023 were $385.2 million. In addition, as of June 30, 2023, cash receivables from the Company’s collaboration with ONO were $2.8 million. • Total Revenue: Revenue was $0.9 million for the second quarter of 2023, which was derived from the Company’s conduct of preclinical development activities for a second collaboration candidate targeting an undisclosed”
FATE THERAPEUTICS INC shareholders approved Non-binding advisory vote to approve compensation of named executive officers at the 2023-06-06 meeting.
“Non-binding Advisory Vote on Compensation of Named Executive Officers. For Against Abstain Broker Non-Votes 73,720,442 2,955,503 61,938 10,211,752”
FATE THERAPEUTICS INC shareholders approved Ratification of the appointment of Ernst & Young LLP as independent registered public accounting firm at the 2023-06-06 meeting.
“Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023. For Against Abstain Broker Non-Votes 85,534,350 197,464 1,217,821 —”
FATE THERAPEUTICS INC shareholders approved Election of three Class I Directors at the 2023-06-06 meeting.
“Election of Class I Directors. Director Nominee For Withheld Broker Non-Votes Robert S. Epstein, M.D., M.S. 74,088,457 2,649,426 10,211,752 John D. Mendlein, Ph.D., J.D. 65,801,671 10,936,212 10,211,752 Karin Jooss, Ph.D. 74,481,093 2,256,790 10,211,752”
Yu-Waye (Wayne) Chu departed as Chief Medical Officer at FATE THERAPEUTICS INC.
“Dr. Yu-Waye (Wayne) Chu, M.D. notified Fate Therapeutics, Inc. (the “Company”) that he intends to resign as Chief Medical Officer of the Company effective as of July 14, 2023 to pursue another opportunity.”
FATE THERAPEUTICS INC reported financial results for first quarter ended March 31, 2023.
“On May 3, 2023, Fate Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2023.”
FATE THERAPEUTICS INC: Amended definition of Beneficial Ownership Limitation in Class A Convertible Preferred Stock Certificate of Designation to 14.99% of outstanding common shares upon conversion (effective 2023-04-13).
“On April 13, 2023, the Company filed with the office of the Secretary of State of the State of Delaware a Certificate of Amendment (the “Certificate of Amendment”) to Certificate of Designation of Preferences, Rights and Limitations of Class A Convertible Preferred Stock (the “Certificate of Designation”) which amends the definition of “Beneficial Ownership Limitation” to be 14.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock pursuant to a Notice of Conversion (as defined in, and to the extent permitted pursuant to Section 6(c) of, the Certificate of Designation).”
FATE THERAPEUTICS INC reported financial results for the fourth quarter and full year ended December 31, 2022.
“On February 28, 2023, Fate Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2022.”
FATE THERAPEUTICS INC announced a restructuring with charges of approximately $15 million (approximately 220 employees).
“On January 5, 2023, the Company announced the prioritization of its current and near-term clinical programs and development plans, including advancement of a second-generation CD19-targeted chimeric antigen receptor (CAR) natural killer (NK) cell program for hematologic malignancies and severe autoimmune disorders, its FT576 CAR NK cell program for multiple myeloma, its FT819 CAR T-cell program for B-cell lymphoma, and its FT825/ONO-8250 CAR T-cell program for solid tumors under its collaboration with ONO Pharmaceutical Co., Ltd.; and discontinuation of its FT516, FT596, FT538, and FT536 NK cell programs. The restructuring plan will result in a reduction in the Company’s workforce to approximately 220 employees, and is expected to be completed during the first quarter of 2023. These changes are expected to extend the Company’s cash runway through 2025. The Company estimates that it will incur charges of approximately $15 million for severance and other employee termination-related cost”
FATE THERAPEUTICS INC terminated Collaboration and Option Agreement with Janssen Biotech, Inc. (effective 2023-01-03).
“On January 3, 2023, Fate Therapeutics, Inc. (the “Company”) received notice of termination from Janssen Biotech, Inc. (“Janssen”) of the Collaboration and Option Agreement dated April 2, 2020 by and between the Company and Janssen (the “Collaboration Agreement”), pursuant to which Janssen and the Company had agreed to collaborate to develop iPSC-derived CAR NK- and CAR T-cell product candidates for the treatment of cancer.”
Mark Plavsic was terminated as Chief Technical Officer at FATE THERAPEUTICS INC.
“the employment of Mark Plavsic, Ph.D., D.V.M., the Company’s Chief Technical Officer, is expected to terminate effective as of March 6, 2023.”
FATE THERAPEUTICS INC entered into Letter Agreement with Ono Pharmaceutical Co., Ltd. valued at $12.5 million (effective 2022-11-07).
“On November 7, 2022, Fate Therapeutics, Inc. (“Fate”) and Ono Pharmaceutical Co., Ltd. (“Ono”) entered into a letter agreement (“Letter Agreement”) in connection with the Collaboration and Option Agreement between Fate and Ono dated September 14, 2018, as amended by a letter agreement dated December 4, 2020 and an amendment dated June 28, 2022 (the “Agreement”).”
FATE THERAPEUTICS INC reported financial results for the third quarter ended September 30, 2022.
“On November 3, 2022, Fate Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2022.”
Yuan Xu was appointed as Class II director at FATE THERAPEUTICS INC.
“On August 3, 2021, the Board appointed Yuan Xu, Ph.D. to the Board as a Class II director.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.